Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.75 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.75 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.75 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.75 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.75 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.75 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.75 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.75 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.75 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.75 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.75 |
| ▸ | SSTR2 | P30874 | 8/20 | 0.69 |
| ▸ | SSTR5 | P35346 | 8/20 | 0.69 |
| ▸ | SSTR4 | P31391 | 6/20 | 0.69 |
| ▸ | SSTR3 | P32745 | 3/20 | 0.69 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.60 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10795629 | 0.96 | HDAC3 (0.72) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL11029594 | 0.96 | HDAC3 (0.72) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1373163 | 0.92 | SSTR2 (0.64) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL24173210 | 0.89 | HDAC3 (0.66) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Hymenamide J SCHEMBL31603791 | 0.88 | HDAC3 (0.67) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL10827586 | 0.88 | SSTR5 (0.68) | SSTR2SSTR5SSTR4SSTR3 | |
| SCHEMBL10794973 | 0.88 | HDAC3 (0.65) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL24172946 | 0.86 | HDAC3 (0.62) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL29356129 | 0.85 | SSTR4 (0.65) | SSTR2SSTR5SSTR4SSTR3 | |
| SCHEMBL24173211 | 0.85 | NECTIN4 (0.60) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057913-A1 | USE OF SOMATOSTATIN AGONIST IN THE TREATMENT OF SSTR3 EXPRESSING TUMORS | ITALFARMACO SPA (IT) | 2025-02-20 | — | — | US | disclosed |
| EP-4452293-A1 | USE OF SOMATOSTATIN AGONIST IN THE TREATMENT OF SSTR3 EXPRESSING TUMORS | Italfarmaco SpA (IT) | 2024-10-30 | — | — | EP | disclosed |
| CN-118574631-A | Use of somatostatin agonists in the treatment of tumors expressing SSTR3 | 意大发马克股份公司 | 2024-08-30 | — | — | CN | disclosed |
| WO-2023118437-A1 | USE OF SOMATOSTATIN AGONIST IN THE TREATMENT OF SSTR3 EXPRESSING TUMORS | ITALFARMACO S.P.A. (IT) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250057913-A1 | USE OF SOMATOSTATIN AGONIST IN THE TREATMENT OF SSTR3 EXPRESSING TUMORS | SSTR3, SSTR1, SSTR5 | HDAC3 1230/4885HDAC4 1756/4885HDAC1 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.